Investment analysts at Alliance Global Partners started coverage on shares of Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) in a research report issued on Wednesday. The firm set a “buy” rating and a $50.00 price target on the stock.
Palatin Technologies Price Performance
About Palatin Technologies
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
Featured Stories
- Five stocks we like better than Palatin Technologies
- What is a SEC Filing?
- Palantir Stock Finds Its Footing—and a Path to Global Growth
- What is the Nikkei 225 index?
- The $100 Million Tell: Following Smart Money Into DoorDash
- Canada Bond Market Holiday: How to Invest and Trade
- Wall Street’s Sleeping Giant: Is Amazon About to Wake Up?
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
